Novo Nordisk appoints Curtis Oltmans to US executive team

pharmafile | January 8, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |  Novo Nordisk, Oltmans 

Novo Nordisk has announced that Curtis Oltmans has been promoted to corporate vice president and general counsel, Legal and Quality Affairs and joins the firm’s US executive team.

In his new role Oltmans is responsible for strategy and initiatives in the areas of law, quality, intellectual property, grants and philanthropy for the company’s business in North America.

Previously, as vice president and deputy general counsel, Oltmans lead the Legal Affairs team. He was tapped in 2010 to lead Novo Nordisk’s Native American Health Initiative, a project designed to build sustainable diabetes care and education programs with the Rosebud Sioux Tribe in Rosebud, South Dakota.

Advertisement

“Curt has used his extensive knowledge of the pharmaceutical industry to make significant contributions during his tenure so far at Novo Nordisk,” said Jerzy Gruhn, president, Novo Nordisk. “He has led our legal team through a number of significant milestones, along with overseeing an important social responsibility effort for the Native American community. We look forward to his continued leadership as a part of the executive team.”

Oltmans joined Novo Nordisk in June 2005. Prior to this he held various positions in the legal department of Eli Lilly (1992-2005), including positions based in Europe and the US. 

Related Content

hsm_mobile_clinical_trial_istock-872676342

FDA approves Wegovy for treatment of MASH in adults with liver fibrosis

The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …

BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation

BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …

obesity

Pila Pharma raises SEK 20m to advance new oral obesity treatment

Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital …

The Gateway to Local Adoption Series

Latest content